Esperion Therapeutics, Inc. (ESPR) Downgraded by BidaskClub

BidaskClub cut shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) from a strong-buy rating to a buy rating in a research note published on Friday morning.

A number of other analysts also recently weighed in on the company. Zacks Investment Research downgraded Esperion Therapeutics from a hold rating to a sell rating in a report on Monday, May 1st. ValuEngine upgraded Esperion Therapeutics from a sell rating to a hold rating in a report on Friday, June 2nd. Citigroup Inc. restated a buy rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Jefferies Group LLC initiated coverage on Esperion Therapeutics in a report on Monday, July 10th. They issued a hold rating and a $55.00 price objective for the company. Finally, Stifel Nicolaus restated a buy rating and issued a $60.00 price objective (up from $45.00) on shares of Esperion Therapeutics in a report on Monday, June 26th. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Buy and an average target price of $38.08.

Esperion Therapeutics (NASDAQ ESPR) traded down 2.99% on Friday, hitting $45.17. The stock had a trading volume of 320,792 shares. Esperion Therapeutics has a 12-month low of $9.40 and a 12-month high of $50.52. The company has a 50 day moving average of $44.47 and a 200 day moving average of $33.65. The company’s market capitalization is $1.02 billion.

Hedge funds have recently modified their holdings of the stock. US Bancorp DE boosted its stake in shares of Esperion Therapeutics by 1.1% in the second quarter. US Bancorp DE now owns 9,856 shares of the biopharmaceutical company’s stock worth $457,000 after buying an additional 104 shares during the period. American International Group Inc. boosted its stake in shares of Esperion Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 584 shares during the period. Nationwide Fund Advisors boosted its stake in shares of Esperion Therapeutics by 2.4% in the first quarter. Nationwide Fund Advisors now owns 39,286 shares of the biopharmaceutical company’s stock worth $1,387,000 after buying an additional 921 shares during the period. SG Americas Securities LLC boosted its stake in shares of Esperion Therapeutics by 74.5% in the second quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 2,991 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in shares of Esperion Therapeutics by 39.4% in the first quarter. Wells Fargo & Company MN now owns 11,602 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 3,282 shares during the period. 85.20% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.